Korean J Med.
2011 Nov;81(5):554-561.
Treatment in Patients with Early-Stage Hodgkin's Lymphoma
- Affiliations
-
- 1Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. chosg@catholic.ac.kr
Abstract
- As there has been much progress in radiation therapy, and effective chemotherapy were introduced, the survival outcome of patients with Hodgkin's lymphoma has been significantly improved. Particularly, more than 90% of the patients with early-stage Hodgkin's lymphoma are expected to survive for at least 5 years. This very high survival rate and increasing recognition of the long-term toxicity of treatment including second malignancies led to current studies designed to reduce or eliminate the radiotherapy and minimize the number of chemotherapy cycles. However, because patients with early-stage Hodgkin's lymphoma are not homogeneous group recognition of risk factors in identification of unfavorable Hodgkin's lymphoma is essential for successful therapeutic strategy. Therefore, we will review risk assessment strategies with reference to publications and discuss current standard therapy to maximize therapeutic outcomes and to minimize late, potentially fatal toxicity in early-stage Hodgkin's lymphoma.
